Explore the words cloud of the Quality2Cells project. It provides you a very rough idea of what is the project "Quality2Cells" about.
The following table provides information about the project.
|Coordinator Country||Germany [DE]|
|Total cost||71˙429 €|
|EC max contribution||50˙000 € (70%)|
1. H2020-EU.3.1.3. (Treating and managing disease)
|Duration (year-month-day)||from 2016-08-01 to 2017-01-31|
Take a look of project's partnership.
|1||IBIDI GMBH||DE (PLANEGG MARTINSRIED)||coordinator||50˙000.00|
Cell-based therapy (CBT) for cure of difficult-to-treat cancer types is the most disruptive innovation in personalized medicine. However, patient-specific production of therapeutic immune cells is expensive and associated with remaining risks. In particular, it is known that only actively migrating immune cells are efficient against tumours cells, while inactive therapeutic cells can elicit adverse effects. Yet, there is no quality control (QC) regarding motility of therapeutic cells before patient treatment. The goal of the proposal is to promote an integrated bench-top instrument for reliable assessment of motility parameters in standardized cell culture carriers, i.e. the TimeLapseReader.
As leading provider of live cell migration assays ibidi strives to market a complete QC solution based on an automated instrument in combination with ready-to-use QC kits, slides and reagents. The TimeLapseReader will allow robust and reproducible migration tests in manufacturing facilities and set a new standard for QC of immune cell in CBT.
In Phase 1 the feasibility study will explore key parameters for QC in the most relevant therapeutic cell types and the best market entry strategy. Objectives include: • Identification of relevant QC parameters for therapeutic cells. • Setting up the business plan including competitor and freedom-to-operate analysis. • Strategy to obtain regulatory approval / CE-Marking for the final device version.
Expected impact is eminent as CBT is going to enter the medical market with serval hundred to thousands of patients treated worldwide per year. It is expected, that up to 20% of all cancer patients can be cured with CTB within 10-15 years assuming serval millions QC per year. ibidi will apply for funding to validate QC tests in a Phase 2 proposal. Phase 2 will consolidate the technology and transform ibidi into a global player of medical QC in the CBT field.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "QUALITY2CELLS" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (email@example.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "QUALITY2CELLS" are provided by the European Opendata Portal: CORDIS opendata.
CeLac and European consortium for a personalized medicine approach to Gastric CancerRead More
PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregiversRead More
Integrating and decentralising diabetes and hypertension services in AfricaRead More